These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15610664)

  • 1. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
    Gotlib J
    Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging treatments in acute myeloid leukaemia.
    Kell J
    Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of farnesyltransferase inhibitors in hematologic malignancies.
    Santos ES; Rosenblatt JD; Goodman M
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
    Bao T; Smith BD; Karp JE
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):287-96, 302. PubMed ID: 16167001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-kit as a target in the treatment of acute myelogenous leukemia.
    Advani AS
    Curr Hematol Rep; 2005 Jan; 4(1):51-8. PubMed ID: 15610660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
    Karp JE; Lancet JE
    Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
    Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
    Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.